Skip to content
drillr.ai
Sign up

300685.SZ

Amoy Diagnostics Co., Ltd.

SZSE · Healthcare · C 制造业 · CN

CNY 18.41
−3.05%
Ask drillr

  • Sep 16, 2026, 08:38 UTC

    Amoy Diagnostics directors and executives, including general manager Luo Jiemin, plan to increase their holdings of the company's shares by up to RMB 10 million in aggregate within three months of the announcement.

    Source:

  • Sep 1, 2026, 09:29 UTC

    Amoy Diagnostics announced that it has repurchased 9.1193 million shares for about 171 million yuan under its buyback program to cancel shares and reduce registered capital.

    Source:

  • Aug 24, 2026, 09:48 UTC

    Amoy Diagnostics reported its first-half 2026 results: revenue of 559 million yuan, down 3.45% year-on-year; net profit attributable to shareholders of 166 million yuan, down 12.12% from 189 million yuan in the same period of 2025; non-recurring net profit of 162 million yuan, down 12.49%.

    Source:

  • Aug 17, 2026, 06:15 UTC

    Japan's Ministry of Health, Labour and Welfare approved Amoy Diagnostics' AiHuiJie (PCR11) as a companion diagnostic for Zongheitinib (Saint-Hetu) in Japan on August 17, 2026.

    Source:

  • Aug 5, 2026, 07:41 UTC

    Amoy Diagnostics and its second-level wholly-owned subsidiary recently obtained two invention patent certificates from the China National Intellectual Property Administration, with the patents already applied to related products.

    Source:

  • Aug 3, 2026, 12:39 UTC

    On the evening of August 3, 2026, 31 STAR Market companies disclosed buyback or shareholding increase progress announcements, including 29 buyback progress updates and 2 shareholding increase updates.

    Source:

  • Jul 27, 2026, 01:51 UTC

    Sinopharm Group acquired IVD leader Amoy Diagnostics for about 1.654 billion yuan.

    Source: